Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Oncolytic Virus
100%
Systemic Delivery
100%
Virus
100%
Cancer Therapy
100%
Tumor
55%
Viral
22%
Metastatic Disease
22%
Immune-competent Host
22%
Cyclophosphamide
22%
Vesicular Stomatitis Virus
22%
Neutralizing Antibodies
22%
Tumor Localization
22%
Phase I Trial
11%
Murine Tumors
11%
Virus Survival
11%
Reovirus
11%
Therapeutic Level
11%
Metastatic Tumor
11%
Novel Protocols
11%
Vascular Barrier
11%
Ongoing Trials
11%
Dose Timing
11%
Virotherapy
11%
Mayo Clinic
11%
Oncolytic Virotherapy
11%
Tumor Vasculature
11%
New Trial
11%
Systemic Agents
11%
Adaptive Response
11%
Physical Barrier
11%
Clinical Model
11%
Regulatory Agencies
11%
Specific Aims
11%
Repeated Administration
11%
Vascular Permeability
11%
Access Control
11%
Administration Time
11%
Host Immune Response
11%
Immune-competent
11%
Medicine and Dentistry
Cancer Therapy
100%
Virus
100%
Oncolytic Virus
100%
Tumor
66%
Metastatic Carcinoma
33%
Vesiculovirus
22%
Neutralizing Antibody
22%
Antivirus Agent
22%
Cyclophosphamide
22%
Tumor Localization
22%
Blood Vessel Permeability
11%
Clinical Trial
11%
Oncolytic Virotherapy
11%
Virotherapy
11%
Adaptive Response
11%
Virus Survival
11%
Extravasation
11%
Reoviridae
11%
Immune System
11%
Tumor Vascularization
11%
Pharmacology, Toxicology and Pharmaceutical Science
Oncolytic Virus
100%
Virus
100%
Malignant Neoplasm
100%
Virotherapy
20%
Neutralizing Antibody
20%
Cyclophosphamide
20%
Vesiculovirus
20%
Antivirus Agent
20%
Neoplasm
20%
Clinical Trial
10%
Tumor Vascularization
10%
Extravasation
10%
Reoviridae
10%